Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pace of progress quickens at ReNeuron as it gets set to launch two clinical trials

Stem cell research group ReNeuron will step up activity after receiving regulatory approval for two clinical trials.
Pace of progress quickens at ReNeuron as it gets set to launch two clinical trials

Stem cell research group ReNeuron (LON:RENE) will step up activity after receiving regulatory approval for two clinical trials.

The first is a phase II study building on its early work with victims of stroke, who will receive its ReN001 investigational therapy.

Hospital trusts involved will recruit 41 patients, treating them eight to 12 weeks post-stroke, which is regarded as the “optimum treatment window” for efficacy.

The second is a phase I investigation into critical limb ischaemia. This is an ailment that results from a marked reduction in blood to the legs, feet or hands and is normally associated with atherosclerosis (furring of the arteries). In all, nine patients will be treated with ReN009.

Both trials will use CTXcryo, the cryopreserved variant of ReNeuron's CTX cell line, which provides the drug product for both the stroke and critical limb ischaemia programmes.

The formulation is cheaper, easier to use and can be stored for longer than its predecessor.

ReNeuron said early adoption of CTXcryo avoids the “likely need for subsequent, time-consuming bridging studies, thereby accelerating time to market".

Chief executive Michael Hunt said: "We are delighted to have received these concurrent clinical trial approvals for our stroke and critical limb ischaemia programmes.

“It is especially pleasing to have been given approval to use our second-generation CTXcryo cells in both of these new clinical trials.

“The fact that this new product variant is being deployed clinically much earlier than we had planned is illustrative of ReNeuron's ability, in collaboration with its various partners, to successfully innovate and sustain its commercial and competitive edge."

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

scientist in lab
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use